News | August 05, 2011

New Studies on Role of Galectin-3 in Heart Failure Presented at ESC 2011

August 5, 2011 — BG Medicine Inc., a company specializing in novel, biomarker-based diagnostics, will present results from several studies utilizing its galectin-3 test at the upcoming European Society of Cardiology (ESC) Congress 2011. The conference will be held Aug. 27-31, in Paris, France.

The presentations will address four important topics related to galectin-3-mediated cardiac disease: (1) the role of galectin-3 in predicting patients' response to heart failure therapy for select drug classes; (2) the ability of galectin-3 to identify individuals at risk for cardiovascular events prior to their first diagnosis of heart failure; (3) the mechanism and role of galectin-3 in heart failure development; and (4) the opportunity to block galectin-3 using natural carbohydrate compounds and their effects on heart failure development.

"When we initiated the development of a galectin-3 diagnostic test, we postulated that galectin-3 could be responsible for a common and important form of cardiac disease that often leads to heart failure. If proven, we expected that patients with galectin-3-mediated heart failure may respond differently to certain drugs, they may be identified before heart failure is first clinically diagnosed, and the built-in ‘on-off switch’ on the galectin-3 protein could be manipulated to block its activity," commented Pieter Muntendam, M.D., president and CEO of BG Medicine. "It is exciting to see that the galectin-3 data support our expectations and that these new data will be presented at the ESC meeting."

In order to provide access to this important information, the company will also host an interactive webinar, "Role of Galectin-3 in Therapeutic and Cardiovascular Outcomes – Results from Leading Studies Presented at the European Society of Cardiology Annual Meeting," at 12 p.m. EDT (18:00 CEST) Aug. 30. The webinar can be accessed via Cardiocare Live, a virtual cardiology congress, presented by the Johns Hopkins University School of Medicine and produced by PlatformQ.

The interactive format provides an opportunity for participants to communicate directly with the researchers who have conducted these studies.

The faculty will feature Bertram Pitt, M.D., FACC, professor of medicine emeritus, University of Michigan School of Medicine, division of cardiology; Lars Gullestad, M.D., Ph.D., professor in cardiology, Rikshospitalet University Hospital, department of cardiology; and Rudolf De Boer, M.D., Ph.D., associate professor in cardiology, University Medical Center Groningen. Pieter Muntendam, M.D., will moderate the session.

The program is sponsored by Abbott, Alere Inc., bioMérieux and Siemens. Further details regarding the webinar will be announced closer to the date.

Galectin-3 is a unique carbohydrate-binding lectin, or protein, that binds to carbohydrates called beta-galactosides. Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure, and is believed to be a primary mediator of progressive cardiac fibrosis (abnormal thickening and stiffening of the heart muscle) and adverse remodeling (changes in the structure of the heart).

For more information: www.bg-medicine.com and www.galectin-3.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init